Isotopia Molecular Imaging Ltd
Isotopia Molecular Imaging Ltd is a notable supplier to the pharmaceutical industry, specialising in the provision of a range of essential services aimed at enhancing the development and delivery of medicinal products.
Description
Founded in 2006 in Israel, Isotopia Molecular Imaging develops, manufactures, and distributes radioactive isotopes and radiopharmaceuticals for both diagnostic imaging and targeted cancer therapy. The company combines expertise in nuclear pharmacy operations with advanced production facilities across multiple regions. It provides comprehensive radiopharmacy services—including PET and SPECT tracer production, cold‑kit assembly, and lutetium‑177 therapies—supported by a robust global manufacturing and distribution network.
Key Products & Services
Theranostics: GMP‑grade lutetium‑177 (non‑carrier‑added and carrier‑added), and terbium‑161 isotopes for personalised cancer treatment.
Diagnostics: Isoprotrace® kit for gallium‑68 PSMA‑11 PET imaging, enhancing prostate cancer detection.
Radiopharmacy Services: Production of PET and SPECT tracers, cold kits, Mo‑99/Tc‑99 generators, and Lu‑177 radioligands via GPP‑certified processes.
finder.startupnationcentral.org
Contract Manufacturing (CMO): Aseptic plant capabilities in Israel for sterile, lyophilised, and aseptic drug products, supporting clinical trials and commercial production.
With state‑of‑the‑art facilities in Israel, Austria, and the United States, Isotopia continues to expand patient access to advanced radiopharmaceuticals worldwide. The firm is actively pursuing regulatory approvals in new markets and forging partnerships to strengthen its position in the field of nuclear medicine. Through its integrated capabilities—spanning isotope production, high‑end radiochemistry and contract manufacturing—it aims to support healthcare providers with reliable, high‑quality solutions that enhance the diagnosis and treatment of complex diseases.